Biotech News

Alector to Participate in Upcoming Healthcare Conferences

Alector (ALEC)AlectorConference / presentation

Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

Cantor Global Healthcare Conference 2025 (New York, New York) Thursday, September 4, 2025, at 3:55 p.m. ET, fireside chat

Morgan Stanley 23rd Annual Global Healthcare Conference (New York, New York) Monday, September 8, 2025, at 10:00 a.m. ET, fireside chat

H.C. Wainwright 27th Annual Global Investment Conference (New York, New York) Tuesday, September 9, 2025, at 1:30 p.m. ET, company presentation

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com . Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com .

Alector Contacts: Alector Katie Hogan 202-549-0557 katie.hogan@alector.com

Argot Partners (media) David Rosen 646-461-6387 alector@argotpartners.com

Argot Partners (investors) Laura Perry 212-600-1902 alector@argotpartners.com

Related news

Alector

Neurodegeneration and Immunology Alector develops therapies for neurodegenerative diseases using insights from human genetics, immunology and neuroscience. Its programs seek to remove toxic proteins, replace deficient proteins and restore immune function in the brain. Alector Brain Carrier The Alector Brain Carrier platform is designed...

Recent company news

Stock data

Close
2.36 USD
Market cap
216.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States